GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $5.80 Average PT from Analysts

Key Points

• GoodRx Holdings, Inc. has received a consensus rating of "Hold" from analysts, with an average price target of $5.80.
• In its latest earnings report, GoodRx reported $0.09 earnings per share, missing consensus estimates, and showed a 1.2% year-over-year increase in revenue compared to the same quarter last year.
• Major shareholder Spectrum recently sold 10,677 shares of GoodRx stock at an average price of $4.80, revealing ongoing insider activity as institutional investors adjust their positions.

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have been given an average rating of "Hold" by the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $5.80.

Several research firms have recently weighed in on GDRX. UBS Group decreased their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $6.00 price objective on shares of GoodRx in a report on Monday, August 11th. Raymond James Financial cut GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. Finally, The Goldman Sachs Group reduced their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, May 9th.

GoodRx Stock Performance

NASDAQ:GDRX traded down $0.01 during mid-day trading on Friday, reaching $4.35. The company's stock had a trading volume of 1,569,793 shares, compared to its average volume of 6,053,919. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. The stock has a market cap of $1.51 billion, a P/E ratio of 43.50, a PEG ratio of 1.90 and a beta of 1.24. The firm's fifty day moving average price is $4.57 and its two-hundred day moving average price is $4.49. GoodRx has a 12-month low of $3.31 and a 12-month high of $8.38.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same quarter in the prior year, the firm earned $0.08 earnings per share. The business's revenue was up 1.2% compared to the same quarter last year. On average, equities analysts forecast that GoodRx will post 0.13 EPS for the current fiscal year.

Insider Buying and Selling

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.53% of the company's stock.

Hedge Funds Weigh In On GoodRx

Several institutional investors and hedge funds have recently bought and sold shares of GDRX. Hohimer Wealth Management LLC raised its stake in shares of GoodRx by 8.2% in the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock worth $155,000 after buying an additional 2,658 shares during the period. SBI Securities Co. Ltd. lifted its position in shares of GoodRx by 13.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock valued at $100,000 after buying an additional 2,748 shares in the last quarter. Gotham Asset Management LLC lifted its position in shares of GoodRx by 31.0% during the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company's stock valued at $82,000 after buying an additional 4,182 shares in the last quarter. Lazard Asset Management LLC raised its stake in GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock worth $85,000 after acquiring an additional 5,201 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after purchasing an additional 7,580 shares in the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.